Olema Oncology names Jason O'Byrne as chief financial officer
The appointment, effective August 11, 2026, comes as the company approaches pivotal data from its OPERA-01 trial and prepares for a potential first commercial launch.
SEC filing
Latest
2 stories
Thursday, August 13
Caribou reports Q2 2026 results, updates vispa-cel and CB-011 data
Caribou cites durable ANTLER and CaMMouflage phase 1 results as it plans a pivotal ANTLER-3 trial, with cash seen lasting into late 2027.
SEC filing